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1.1 Reactive oxygen species (ROS) 
 
Reactive oxygen species (ROS) are a heterogeneous population of active biological molecules 
that is generated both as by-products in aerobic metabolism and also by specialized enzymes 
[1-3]. ROS are generated in all tissues and organs of multicellular organisms, including 
animals, plants and even microbes. These reactive species play different roles in biology 
including host defence, hormone biosynthesis, fertilization and redox signalling that regulate 
mitogenesis, apoptosis and oxygen sensing [4, 5]. They are also involved in several disease 
processes including aging and cancer [2, 4, 6].  
 
The major ROS molecules include hydrogen peroxide (H2O2), the superoxide anion (O2•⎯), the 
hydroxyl radical (OH•) and hypochlorous acid (HOCl) (Fig. 1) [2]. Cellular generation of 
ROS starts with the production of superoxide. Superoxide rapidly dismutases to hydrogen 
peroxide either spontaneously or through catalysis by superoxide dismutase (SOD). The 
formation of hydroxyl radical occurs in the presence of metals like iron and copper by the 
Fenton reaction or Haber-Weiss reaction [7, 8]. Peroxidases are the main source for the 
production of HOCl from H2O2 [9]. ROS are formed as by-products of mitochondrial 
respiration or from oxidases, including nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, xanthine oxidase (XO) and arachidonic acid oxygenases [6, 10, 11].  
 
ROS molecules are implicated in cellular redox signalling that regulate events such as 
proliferation, differentiation, apoptosis, angiogenesis and gene expression. They frequently 
act through redox sensitive cysteine residues on receptors, protein kinases, tyrosine 
phosphatases, as well as on transcription factors. H2O2 is continuously produced and 
maintained at low, nanomolar concentrations in all cells. The level of H2O2 is balanced 
through the action of several peroxidases and antioxidants (see chapter 1.3). This oxidant is 
generated in response to physiological stimuli and is in this context considered as a true 
second messenger. At such low levels, H2O2 can stimulate cell growth, which has led to the 
general recognition that redox signalling pathways have an important role in cellular growth 
[6, 12-14]. Recent studies show that both cellular and mitochondrial ROS have a role in the 





Figure 1: Generation of ROS 
Superoxide (O2•⎯) is generated from various sources such as NADPH oxidase, xanthine oxidase, mitochondrial respiratory chain. 
Two molecules of superoxide can react to generate hydrogen peroxide (H2O2) in a reaction called dismutation. This reaction is 
accelerated by the enzyme superoxide dismutase (SOD). In the presence of iron superoxide and hydrogen peroxide generate 
hydroxyl radicals (OH•). Superoxide can also be converted in to peroxynitrate (ONOO-) in the presence of nitric oxide (NO). In the 







1.2 Oxidative stress 
 
Oxidative stress is defined as an imbalance in pro-oxidants and antioxidants which results in 
macromolecular damage and dysfunction of redox signalling and control [16]. This imbalance 
of oxidants leads to overall excessive production of ROS and may result in damage of 
macromolecules as well as disruption of redox signalling [17]. When the ROS levels are 
raised above a certain threshold the defence system of antioxidants may become inhibited. 
This may then lead to DNA mutation or DNA damage, genome instability and cancer 
initiation and progression [6, 18]. Increased oxidative stress leads to variety of diseases such 
as cancer, neurodegenerative disorders, asthma, pulmonary fibrosis and aging [17, 19]. 
 
Data show that (a) some growth factors such as epidermal growth factor (EGF), insulin, and 
angioprotein-1 increase ROS production in the ovarian cancer cells in order to regulate cell 
migration and proliferation; (b) high levels of ROS are observed in some cancer cells, which 
may induce DNA damage leading to genomic instability and tumour initiation; (c) ROS 
induce the activation of mitogen activated protein (MAP) kinase, nuclear factor κB (NF-κB), 
and activator protein 1 (AP-1), which are all known to be associated with cancer 
development. The direct role of ROS in tumour growth and angiogenesis remains undefined 
[20, 21]. However, it has been shown that hypoxia and hypoglycemia may result in increased 
ROS production in mitochondria and lead to malignant transformation [6].  
 
 
1.3 Antioxidants  
 
The cellular production of ROS is balanced by several antioxidant systems, including various 
enzymatic systems and antioxidant molecules. The enzymatic systems include among others 
SOD, catalase, GSH peroxidases, thioredoxin reductase and peroxiredoxin. The coordinated 
action of the antioxidant enzymes makes sure that ROS levels are balanced. Excessive 
production of ROS will lead to oxidative damage of many macromolecules and will also alter 
the intracellular redox homeostasis. Antioxidants are critical for life and they are mainly 
divided into two types; exogenous antioxidants supplied with the diet, and endogenous 







Glutathione (GSH) is a tripeptide (γ-glutamyl-cysteinyl-glycine) and is the most abundant 
non-protein thiol in cells being present in millimolar concentrations [23]. GSH has antioxidant 
functions and also multiple biological functions such as detoxification of xenobiotic 
compounds, and thiol-disulfide exchange reactions in the maintenance of normal cellular 
redox status [24]. It is also described as a short time reservoir of cysteine [14]. GSH is most 
abundant in the cytosol (85-90% of the cellular pool). Other pools of GSH are found in 
mitochondria, nuclear matrix and peroxisomes [25, 26]. GSH exits in two forms, one is the 
thiol reduced form (GSH), and the other is the oxidized form (GSSG). Under normal redox 
conditions it exits mostly in the reduced form. 
 
GSH synthesis 
GSH is synthesized from glutamate, cysteine and glycine in the cytosol by two sequential 
ATP-dependent reactions. These reactions are catalyzed by two cytosolic enzymes. 
 (1) glutamate + cysteine + ATP                 γ-glutamyl-cysteine + ADP + Pi 
 (2) γ-glutamyl-cysteine + glycine + ATP                 GSH + ADP + Pi 
 
The first step is catalyzed by glutamate cysteine ligase (GCL), also known as γ-
glutamylcysteine synthetase, which is both the rate limiting and the regulatory reaction. In this 
reaction a peptidic γ-linkage is formed by the reaction of γ-carboxyl group of glutamate and 
cysteine. This protects the GSH from hydrolysis by intracellular peptidases. This reaction 
requires Mg2+ or Mn2+. The second step is catalysed by GSH synthase (GS), also known as 
GSH synthetase [26, 27]. One important factor that regulates the de novo GSH synthesis is the 
availability of cysteine. In fact, cysteine is rate-limiting in GSH biosynthesis. Extracelluar 
GSH cannot be taken up by most cells, and γ-glutamyltransferase (GGT) is the only enzyme 
that is able to hydrolyze the peptidic γ-linkage of GSH. Cells that express GGT activity will 
thus have an ability to obtain cysteine from extracellular hydrolysis of GSH [25, 27]. 
(See Fig. 4 the γ-glutamyl cycle) 
  
GSH redox cycle 
The antioxidant power of GSH is related to the GSH peroxidase reaction, in which H2O2 is 




of enzymes present in the cytosol or nucleus of most cells. They show different cellular levels 
and subcellular locations, as well as substrate specificities [28].  
 
Figure 2. The GSH redox cycle 
 
The reduction of H2O2 to H2O is catalyzed by glutathione peroxidases (GPx) using GSH as reducing agent. The oxidised glutathione 
disulfide (GSSG) can be reduced back to GSH with glutathione reductase (GR) using NADPH as reducing agent. The oxidised 
NADP+ can be reduced in the pentose phosphate shunt, using the oxidation of glucose 6-phosphate to 6-phosphogluconlactone 








1.4 The NADPH oxidase (NOX) family 
 
NADPH oxidase was first identified in phagocytic cells such as neutrophils and macrophages. 
In phagocytic cells, ROS generation occurs during the oxidative burst by the plasma 
membrane NADPH oxidases [2]. It was for many years thought that ROS production was 
restricted to phagocytic cells. Recent findings however show that NADPH oxidases are found 
in different cells that have no role in host defence. For example, NOX components have been 
reported in fibroblasts, mesangial cells, endothelial cells, osteoclasts and chondrocytes [10]. 
The production of ROS is low in these cells compared to neutrophils. Altered production of 
ROS may lead to immunodeficiency, hearing loss and thyroid problems, cardiovascular 
pathologies, neurodegeneration and possibly cancer [2, 29]. Recently it was shown that ROS-
producing NADPH oxidases, distantly related to animal Nox enzymes exist in a variety of 
eukaryotes including plants, fungi, and the myxomycete (Mycetozoa) Dictyostelium 
discoideum [5]. 
 
The human genome contains genes for 7 members of NADPH oxidase (NOX) family;   
NOX1, NOX2 (also known as gp91phox), NOX3, NOX4, NOX5, and the dual oxidases 
DUOX1 and DUOX2 [2, 5]. All members contain at least six transmembrane domains, motifs 
for NADPH and FAD binding, as well as conserved paired histidines that could ligate heme 
groups (Fig 3). NOX5, DUOX1 and 2 have additional structural features not shared by the 
other NOX proteins. All three have cytosolic EF-hands that are involved in calcium 








Figure 3: NOX family members and their regulatory subunits. 
NOX1-4, the transmembrane subunit p22phox associates with active and inactive NOX. Ca2+ binding to EF-hand domains in the 
cytosol is involved in activation of NOX5 and DUOX1/2 [30] (with permission from publisher). 
 
All NOX family members share common structural similarities, but the activation of each 
member is different. The enzymes have specific biological roles through a regulated 
superoxide generation in response to growth factors, cytokines and calcium signals [3]. 
Superoxide is rapidly converted to hydrogen peroxide, which may regulate target molecules 
through oxidation of sensitive cysteine-residues at low concentrations. Thus, the NOX 







The NOX enzymes are classified into three main groups according to the presence of specific 
domains. The first group consists of NOX1, NOX3 and NOX4. They are nearly identical in 
size and structure to NOX2 and they contain the electron transfer centres that are required to 
pass electrons from NADPH to molecular oxygen in order to form superoxide. NOX5 belongs 
to the second group and builds on the basic structure of NOX2 but differs from other NOX 
isoforms by the presence of intracellular amino terminus containing four binding sites for 
calcium. NOX5 have in addition similarities with plant oxidases, such as the Atrbohs gene 
identified in Arabidopsis [32], with two calcium binding EF-hand motifs in the N-terminal 
elongation. The third group, the dual oxidases DUOX1 and DUOX2 (also known as Thox and 
Lnox) further extends the NOX5 structure by an N-terminal peroxidase domain that is 
separated from the dual EF-hands by an additional transmembrane segment. Duox homologs 




The catalytic subunit of the phagocytic NADPH oxidase is a membrane localized highly 
glycosylated protein [5]. It was earlier known as gp91phox, and is now called NOX2 and is 
the best studied protein of the NOX family members. It is highly expressed in phagocytic 
cells but it was also found in B lymphocytes, neurons, cardiomyocytes, skeletal and smooth 
muscle, hepatocytes, endothelium and haematopoietic stem cells [2]. The NOX2 protein 
contains six transmembrane α helices. The third and fifth helices contain two variant histidine 
residues which coordinate two hemes [2, 5, 11]. The C terminal part folds into a cytoplasmic 
domain containing the FAD and NADPH binding sites.  
 
Activation of NOX2 is a complex process with several co-factors. The transmembrane 
p22phox protein plays a major role in the activation and has two major functions; one is to 
bind the NOX proteins leading to protein stabilization and the other is binding to the organizer 
subunits [2]. These are the small GTPase Rac1, p47phox or its equivalent NOX organizer 1 
(NOXO1), p67phox or its equivalent NOX activator 1 (NOXA1), and p40phox. In phagocytic 
cells, NOX2 binds to p22phox in close association in both intracellular and plasma 
membranes to form cytochrome b558, the catalytic component of the phagocytic NADPH 
oxidase [35]. In the resting conditions an auto-inhibitory region (AIR) prevents the binding of 
p47phox to p22phox [3]. Upon phagocytosis, or during stimulation of cells, phosphorylation 




along with the other cytosolic subunits p67phox, p40phox and Rac1 translocate to the 
membrane and interact with the cytochrome b558 complex [36]. The active NOX2 complex 
transports electrons from cytoplasmic NADPH to extracellular or phagosomal oxygen to 
generate superoxide [4, 5, 37]. NOX2 is reported to be mainly located in the submembranous 
phagosomes in neutrophils, endosomes [38], in the plasma membrane or perinuclear 
membranes [30, 39]. Deficiency of NOX2 has been reported in chronic granulomatous 




NOX1 was the first recognised homologue of NOX2. NOX1 contains 564 amino acids and 
shows 56% identity at protein level to NOX2 [41]. It is highly expressed in colon epithelial 
cells, and also present in several other tissues including smooth muscle, uterus, prostate, 
kidney, stomach and cells such as osteoclasts. NOX1 contains six transmembrane domains 
and conserved motifs corresponding to binding sites of heme, flavin and NADPH [29]. 
Activation of NOX1 requires the cytosolic NOX Organizer1 (NOXO1), a homologue of 
p47phox, and NOX Activator1 (NOXA1) a homologue of p67phox [2]. NOXO1 contains the 
functional domains of p47phox in the same configuration: an amino terminal phox homology 
(PX) domain, two tandem Src homology 3 (SH3) domains and a carboxy terminal, proline 
rich motif serving as an SH3 domain binding site. NOXO1 has domain architecture similar to 
p47phox, except the absence of the AIR. The absence of AIR makes NOXO1 prelocalized at 
membranes together with NOX1 and p22phox. This may be responsible for some constitutive 
activity of NOX1. Similar to p67phox, NOXA1 contains four amino-terminal 
tricodecapeptide repeat (TPR) domains that bind Rac1, a phox and Bem1 (PBI) domain, and a 
single, carboxy terminal SH3 domain that binds NOXO1. It has been shown that the 
transmembrane protein p22phox is also required for NOX1 activity. The best studied 
activation of NOX1 is occurs via angiotensisn-ΙΙ (Ang ΙΙ) in vascular smooth musle cells by 
the activation of protein kinase C (PKC) [42].  Invitro studies showing that cell stimulants 
such as phorbol esters, increases the NOX1 activity by up to 2-fold in many cell systems [43]. 
Rho GTPases also play a role in NOX1 activity. Currently, only guanine nucleotide exchange 
on Rac1 is documented as a regulatory factor for NOX1. In vascular smooth muscle NOX1 
localizes to the cell surface, possibly corresponding to caveolar localization [29, 44]. In 




The physiological role of NOX1 is currently unknown. The many reported roles of NOX1 
may reflect that it has various roles in different cells. May be the role of NOX1 depends 
where the enzyme is expressed and the cell lines studied. NOX1 expression is upregulated by 
growth factors and growth related agonists like angiotensin. It has been shown that NOX1 is 
involved in the development of angiotensin II-induced hypertension in NOX1 deficient mouse   
[45]. In addition, several factors have been reported to up regulate the NOX1 expression such 
as urokinase plasminogen activator (uPA), platelet derived growth factor, bone morphogenic 




NOX3 is a 568 amino acid protein which shows 58% amino acid sequence identity to NOX2 
[41, 46]. The major site for NOX3 expression is the inner ear, but it has also been found in 
several fetal tissues including kidney, liver, lung and spleen [29]. NOX3 forms a complex 
with p22phox to produce ROS. NOX3 is constitutively active compared to NOX1 and NOX2; 
and there is a limited role of the cytosolic co-factors in its activation. NOX3 dependency on 
NOXO1 is species specific. Human NOX3 depends on NOXO1 whereas murine NOX3 
depends on both NOXO1 and NOXA1 [4]. Several studies show a possible role of Rac1 in the 
NOX3 activation, but it is not well documented [43]. The intracellular localization of NOX3 
is currently not known. It has been shown that NOX3 along with p22phox localized to the 
plasma membrane in HEK293 cells [29, 30].  Deficiency of NOX3 leads to severe balance 




NOX4 was originally called Renox (renal oxidase) since NOX4 is most expressed in the 
kidney. NOX4 is a 578 amino acid protein with 39% homology to NOX2 [29]. NOX4 mRNA 
has been found in many tissues and cells including fetal liver, vascular endothelial cells, 
smooth muscle cells, murine osteoclasts, hematopoietic stem cells, adipocytes and also in 
cancer cells including various prostate cancers [49, 50]. NOX4 requires p22phox for its 
activity and it does not require any other regulatory subunits [43].  The complex of NOX4 and 
p22phox is constitutively active. It was reported that NOX4 can have effects on insulin 
signalling cascade via the production of H2O2 in adipose cells. This increased ROS production 




phosphatases [51]. NOX4 may be localized to focal adhesions, the perinuclear endoplasmic 




NOX5 is a 737 amino acid protein and has a 27% identity at the protein level to NOX2 [41]. 
NOX5 is mainly expressed in spleen, testis and in fetal tissues. RT-qPCR experiments 
showed that NOX5 mRNA was detected in several other tissues and cells including ovary, 
placenta, pancreas, vascular smooth muscle, bone marrow and uterus [29]. The enzymatic 
activity of NOX5 dependent on calcium and NOX5 has a N-terminal domain containing four 
calcium-binding EF-hand motifs [43]. Calcium ions activate NOX5 by binding to the EF-
hands and this binding change the conformation of this domain. This enables an 
intramolecular interaction between the N-terminal and C-terminal domains [29]. 
 
1.4.6 DUOX1 and DUOX2 subunits  
 
Dual oxidases (DUOX) were previously called thyroid oxidase because they were initially 
described in the thyroid gland. The name DUOX derived from the protein structure analysis 
of C.elegans NADPH oxidase family [29, 55, 56]. Human DUOX1 protein contains 1551 
amino acids whereas DUOX2 contains 1548 amino acids. Both show 83% DNA sequence 
similarity to each other. DUOX1 shows 53% similarity to NOX2 and DUOX2 shows 47% 
resemblance to NOX2 but there promoters are different [55-57]. Human DUOX1 is highly 
expressed in pancreas, lung, placenta, prostate, testis and salivary glands. Human DUOX2 is 
highly expressed in the trachea, stomach, colon and rectum [43]. 
 
The DUOXs are glycoproteins containing seven transmembrane helices, an extracellular 
peroxidase-like domain, a long intracellular loop with two calcium binding EF-hand motifs 
like NOX5, a FAD binding domain and four NADPH binding sites. The presence of EF-hand 
motifs suggests an important role of calcium ions in regulating the enzymatic activity of 
DUOX in thyroid cells and also in human bronchial epithelial cells. These cells show a high 
expression of DUOX proteins [43, 56]. Characterization of the function and regulation of 
DUOXs had not been fully understood until the discovery of DUOX maturation proteins 
DUOXA1 and DUOXA2 [58]. Partially glycosylated DUOX2 remains in the endoplasmic 




the plasma membrane to generate hydrogen peroxide. DUOX maturation proteins help 
DUOXs to exit from the ER and move to their appropriate location at the plasma membrane 
[43, 56]. A physiological role of DUOX2 has been identified by studying patients who have 
hypothyroidism. These patients have mutations in the DUOX2 gene, but not in the DUOX1 
gene. In addition, it has been shown that ROS generated by DUOX2 have an important role in 
controlling gut epithelial infection [29, 30, 59]. 
 
1.5 Mitochondrial production of ROS 
 
Mitochondria is a major source for the production of superoxide (O2•⎯) and hydrogen peroxide 
(H2O2). Mitochondria consume 90% of cellular oxygen and of that 2-4% is converted into 
ROS [60-63]. The primary production of ROS in mitochondria is O2•⎯ which rapidly is 
converted into the more stable H2O2 by the action of MnSOD and Cu/Zn-SOD in the 
intermembrane space [63]. Many mitochondrial enzymes are known to generate ROS, for 
example the Electron Transport Chain (ETC) complexes I, ΙΙ and ΙΙΙ, the tricarboxylic acid 
cycle enzymes aconitase 2 and α-ketoglutarate dehydrogenase, pyruvate dehydrogenase and 
glycerol-3-phosphate dehydrogenase and cytochrome b5 reductase [60]. Production of O2•⎯ 
varies from organ to organ. In heart and lung O2•⎯ is mainly produced from complex ΙΙΙ and in 
brain pyruvate and α-ketoglutarate dehydrogenase are important ROS sources through 
complex Ι [64, 65]. 
 
Mitochondria contain various antioxidant systems to detoxify the effects of ROS. Enzymatic 
sources include MnSOD, catalase, GPX and non-enzymatic sources including ascorbic acid, 
reduced coenzyme Q10 and GSH. The MnSOD eliminates the O2•⎯ formed in the matrix or on 
the inner side of the inner membrane. GPX helps to detoxify the H2O2 and in heart 
mitochondria catalase plays the important role in detoxification of H2O2 [60, 65, 66]. 
 
Mitochondrial O2•⎯ and H2O2 can modulate several signalling proteins such as c-jun N-
terminal kinase (JNK) in primary cortical neurons and PKC in primary cultured hepatocytes 
and they can activate apoptotic and necrotic pathways [67, 68]. Many oncogenic proteins like 
p53, MYC, STAT-3 and Ras can modulate the mitochondrial function by changing the 
expression of genes in the mitochondria [6]. Hypoxia and glucose deprivation may lead to 
elevated ROS production in the mitochondria which, over time, may stabilize cells via 




to malignant transformation in the mitochondria, resulting in escape from senescence and 
facilitating growth [6]. In normal fibroblasts mutant Ras can induce the senescent cell cycle 
arrest by increasing the mitochondrial mass, the mitochondrial DNA, and the mitochondrial 
production of ROS. These studies showed that mitochondrial dysfunction leads to low ATP 
levels and activation of AMP-activated kinase (AMPK) [69]. In another study on p53 
knockdown, human primary fibroblasts decreased superoxide production in both 
mitochondrial and cellular level and disrupted cellular ROS homeostasis were demonstrated. 
This indicates the possible effect by p53 on mitochondria and the production ROS [70].   
 
Several studies have shown that there is a link or crosstalk between NOX system and the 
mitochondria mediated ROS (for reviews see [6, 71]). In human osteosarcoma cells 
downregulation of NOX1 was observed when the mitochondria genes were inactivated. This 
resulted in low O2•⎯ production by NOX1. In this study the authors claimed that NOX1 is  
localized in the mitochondria and when mitochondria lose control on the NOX1 activity this 
may lead to carcinogenesis in breast and ovarian cells [61]. Mitochondrial ROS activate PKC 
which triggers a vicious cycle on NOX activation [71]. Studies on human 293T cells showed 
that production of ROS is high when these cells are grown in serum depleted medium through 
stimulation of both mitochondria and NOX1. In this study the authors showed that ROS 
produced by mitochondria was not enough to promote the cell death which requires further 
action of NOX1[72].  
 
1.6 Gamma-glutamyltransferase (GGT) 
 
γ-Glutamyltransferase (GGT) (E.C. 2.3.2.2; (5-L-glutamyl)-peptide:amino acid 5-
glutamyltransferase) is found expressed in bacteria, plants and in the animal kingdom 
including humans [73]. GGT is an important enzyme for GSH homeostasis and is the only 
known enzyme that catalyses the hydrolysis of the unique γ-glutamyl group of GSH. By 
initiating the breakdown of extracellular GSH, GGT provides the cells with cysteine, the rate-
limiting substrate for GSH biosynthesis [74].  
 
Structure 
GGT is a heterodimeric plasma membrane bound glycoprotein located on the outer surface of 
the membrane [75]. The apparent molecular weight of the heavy chain is 50 to 62 kDa and the 
light chain 22 to 30 kDa. The variation in molecular weight is due to the degree of 
Introduction 
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glycosylation of the chains that differ in various tissues [75, 76]. The light chain includes the 
active site while the heavy chain is transmembraneous and anchors the protein to the plasma 
membrane [77, 78]. The enzyme is translated as one polypeptide chain, which is catalytically 
inactive, and is further processed into the heterodimeric form after glycosylation in the Golgi 
[75]. The heavy glycosylation (about 30% of the enzyme isolated from liver is carbohydrate) 
prevents cleavage and inactivation by proteases [79, 80].  
  
Function 
GGT catalyzes the transfer of the γ-glutamyl moiety from GSH. The enzyme acts both as a 
glutathionase that is hydrolysing GSH to glutamate and cys-gly and as a transpeptidase by 
transferring the γ-glutamyl group to acceptors such as amino acids and dipeptides including 
cystine. These two types of catalytic reactions can be written as [81]:  
 
1) The transfer or transpeptidase reaction: the γ-glutamyl-group is transferred to 
accepting aminoacids or dipeptides.  
γ-glu-cys-gly + aminoacid (peptide)   GGT    γ-glutamyl-amino acid (peptide) + cys-gly 
 
2) Hydrolysis: in this reaction water will accept the γ-glutamyl residue and GGT acts as a 
glutathionase. 
γ-glu-cys-gly + H2O              glutamic acid + cys-gly 
 
The cysteinylglycine product is further cleaved to cysteine and glycine by plasma membrane 
dipeptidases [24, 82]. The resulting amino acids are taken up by the cells and used for 
intracellular biosynthesis of GSH. GGT is part of  the γ-glutamyl cycle suggested by Meister 







Figure 4. The γ-glutamyl cycle: GSH biosynthesis and salvage 
GSH is synthesised from the constituent amino acids in two reactions, which are catalysed by glutamate cysteine ligase (GCL, 
reaction 1) and glutathione synthase (GS, reaction 2). Each reaction needs ATP. For synthesis, cysteine is obtained through uptake of 
extracellular cysteine or cystine through the ASC and the xc- transporters, respectively. Extracellular GSH is also a cysteine 
reservoir, being degraded by γ-glutamyltransferase, GGT (reaction 3) and the action of various peptidases (reaction 4).  Figure is 
modified from [84]. 
 
GGT acts both on reduced and oxidised glutathione, and on S-conjugated GSH compounds 
including xenobiotics and leukotriene B4. Leukotrienes are biologically active lipid 
derivatives synthesized in hematopoietic cells which are involved in inflammation. GGT 
cleaves and removes the γ-glutamyl moiety from leukotriene LTC4 to give LTD4 [85]. 
Lieberman et al. have shown that GGT deficient mice have highly elevated plasma and urine 
GSH levels and growth retardation due to low levels of cysteine. They also found that 
deficiency of GGT may cause dysfunction of mouse reproductive system and severe cataract 
development [86-88]. Therefore, GGT is a critical enzyme in maintaining GSH and cysteine 
homeostasis and for cellular antioxidant function, as it acts as a glutathionase that helps the 
cells to use extracellular glutathione as a source of cysteine. Studies on the colon carcinoma 
cell line HT29 have shown that cysteine deficiency leads to imbalance between GSH/GSSG 






Human GGT gene structure 
The GGT gene is present as a single copy in mice and rats. In humans, GGT belongs to a 
multigene family that contains at least seven different genes. Among these, only 4 are 
expressed and only GGT1 and 5 have been found to encode proteins exhibiting GGT activity 
[85]. Among all GGT genes the GGT1 is well studied and is translated into a single protein 
that can be cleaved into a light and a heavy chain. All GGT genes are assigned to 
chromosome 22 on q111-q112 close to the BCR and Ig-λ loci  [91]. It has been shown by 
southern blot analysis that human and rat GGT sequences are almost 90% homologous. 
Several human GGT1 cDNAs have been cloned from hepatoma cells (HepG2), placenta, lung 
and fetal liver. These GGT transcripts exhibits different 5´-UTRs but share the same coding 
sequence (Fig. 6) [92]. This difference may reflect tissue specific splicing or the presence of 









Figure 6: Structure of the human GGT mRNAs 
The reading frame of type 1 mRNAs is represented by black boxes. The pink colour boxes represent 5’-UTRs common to the 
mRNAs. Different colours represent specific 5’UTRs. The mRNAs are designated by the tissue from which they were cloned. 
Nucleotides are numbered from A (+1) in the initiation codon. Roman numerals refer to the 5’-non coding exons. Figure is modified 





Regulation of expression 
Acute oxidative stress will reduce the cellular GSH level, and it is well documented that cells 
can respond to lower amounts of oxidants to increase the GSH synthesis [95-97]. This 
synthesis appears to be a concerted action involving GCL, GGT and other enzymes of the γ-
glu cycle [98, 99]. The expression of GGT is upregulated after exposure of lung cells and 
colon carcinoma cells to menadione, a redox cycling quinone [100], hyperoxia [101] and 
nitric acid [102]. GGT is also upregulated by other agents that may induce oxidative stress, 
such as hormones, carcinogens, and inflammatory cytokines [103-105]. ERK1/2 and 
p38MAPK signaling pathways are involved in the rat GGT P5 promoter activation mediated 
by 4-Hydroxynonenal (HNE). It was shown that Ras and its downstream targets P13K/Akt, 
ERK1/2, and p38MAPK were involved in rat GGT P2 promoter activation by menadione in 
CC531 cells [106, 107]. In V79 cell line the production of ROS by GGT activates the NF-κB 
signaling [108].       
 
Subcellular localisation and organ distribution 
In normal human tissues GGT is located to the luminal surface of secretory and absorptive 
cells throughout the body, including sweat glands, breast ducts, prostate, salivary gland ducts 
and the proximal tubules of the kidney [109]. In addition, the GGT protein is expressed at 
high levels in biliary epithelium and brain capillaries [92] . GGT expression may vary during 
organ development; thus GGT levels are high in fetal liver and low in adult liver. On the other 
hand the kidney GGT levels are low at birth but increases with age [93].  High GGT activities 
are also measured in pancreas and prostate [77, 78, 110]. 
Abnormal levels of GGT are often observed in tumors of a variety of tissues including 
hepatocellular carcinomas, malignant squamous carcinomas of the skin, squamous cell 
carcinomas of the buccal pounch epithelium and adenocarcinomas of the lungs [74]. In 
melanoma cells it was shown that overexpression of GGT increased the metastatic growth of 
the cells in mouse liver [111]. 
 
Clinical applications 
GGT is normally found in serum and has been used as a marker for liver diseases for more 
than 70 years [73, 81]. GGT activity measurements in blood was originally suggested to be a 
diagnostic marker of liver alcoholic damage, but is now used more widely in relation to 
inflammation, jaundice and liver cancer. GGT serum levels will increase with age and is 
higher in males than females. Alcohol consumption, drug intake and excessive weight 




GGT is associated with higher risk of cancer in both men and women [112, 113], and recently 
GGT is reported to be a cardiovascular risk factor [114].    
 
GGT deficiency in humans is very rare and only 7-8 patients have been reported worldwide. 
None of the patients had complete absence of GGT activity and it is not clear which GGT 
gene was mutated in these patients. The symptoms are mental retardation and central nervous 
system deficiencies, but there is no clear evidence for the direct role of GGT [73, 85] . 
 
1.7 Redox signalling in cancer 
 
Oxidants, in particular H2O2, acts as second messenger and play central roles in the regulation 
of cellular functions such as proliferation, differentiation and migration. The term redox 
signalling is now an accepted description of how ROS function in signal transduction. At 
normal redox status, cells will respond properly to endogenous and exogenous stimuli, and 
ROS and Reactive Nitrogen Species (RNS) are participating in cellular redox signalling. 
When redox homeostasis is disturbed it may lead to disease development such as cancer and 
degenerative disorders. Many enzymatic and non-enzymatic antioxidants such as SOD, 
catalase and GSH will eliminate excessive ROS and help maintaining the redox homeostasis 
[14, 17].  H2O2 acts mainly through reversible cysteine oxidation on formation of cysteine 
oxidative adduct. Protein tyrosine phosphatases (PTPs), protein tyrsosine kinases (PTKs), 
signalling adaptors and transcription factors are the main targets for the oxidants. In this 
process protein kinases are known to be activated and protein phosphatases inhibited through 
oxidants [6, 115]. 
 
Protein tyrosine phosphatases (PTPs) 
Protein tyrosine phosphatases (PTPs) are well documented targets for ROS. PTPs contain 
cysteine in their active site and the oxidation of cysteine to cysteine sulfenic derivatives leads 
to their enzymatic inactivation which is done by various oxidants including  H2O2 [22, 116]. 
PTPs are divided into two groups; tyrosine specific phosphatases and dual–specificity 
phosphatases. Tyrosine specific phosphatases are PTP1B, Low molecular weight PTP (LMW-
PTP) and Src homology 2 domain containing PTPs (SHP2) and dual specific phosphatases 
include mitogen activated protein kinase (MAPK) phosphatases, tumour suppressor PTEN 
[116, 117]. These phosphatases can be inactivated by H2O2 through cytokines, growth factor- 




insulin signalling pathway. It was shown that insulin stimulated H2O2 production reversibly 
inhibits PTP1B and thus enhanced the early insulin cascade [118].  
 
The phosphoinositide 3-kinase (PI3K) pathway is important in maintaining a number of 
cellular processes including cell proliferation, survival, growth and motility [17, 119]. The 
PI3K pathway can be activated by growth factor receptors such as tyrosine kinase receptor 
and integrin ligand binding [120-122]. It has been shown that TonB.210 cells shows high 
production of ROS. Elevated levels of ROS can activate PI3-K/Akt pathway. They found that 
ROS can increase survival signalling through redox inhibition of PP1 alpha [123].   
 
Many of the components in the PI3K/Akt pathway are redox sensitive; including cys-
dependent phosphatases (CDPs) and protein tyrosine kinases. ROS can oxidize cysteine 
residues of protein tyrosine phosphatases (PTPs) resulting in their inactivation [124]. PTEN is 
a well studied target molecule for ROS in the PI3K/Akt pathway. It has been found that 
hydrogen peroxide inactivates PTEN and activates the PI3-kinase signaling in RAW264.7 
macrophages [125]. Mutations in Tumour suppressor gene PTEN can trigger the tumour 
angiogenesis. Over expression of PI3K active forms can induce the angiogenesis invivo [126]. 
It was shown that ROS will play a role in tumour induced angiogenesis via PI3K/Akt 
signalling in ovarian cancer cells [127]. Mitochondrial ROS oxidize the PTEN which enhance 
the activation of PI3K signaling. This signaling increases the vascular endothelial growth 
factor which is a key regulator in the regulation of angiogenesis.[128]. The consequences of 
inhibiting these molecules leads to irregular Akt signaling which can cause increased cell 
proliferation, enhanced survival and growth [119]. 
 
Protein tyrosine kinases (PTKs) 
PTKs are divided into receptor and non-receptor families and both are important in cellular 
signaling pathways that regulate the cell growth, differentiation, migration and metabolism 
[116]. The receptor tyrosine family includes epidermal growth factor (EGF) receptor, platelet-
derived growth factor (PDGF) receptor and the non-receptor family includes Src, Focal 
adhesion kinase (FAK) and others [129]. ROS can activate PTKs in three different 
mechanisms. First, by altering protein-protein interactions depending on sulfhydryl groups 
and second, inhibiting cysteine residue of the PTPs. This can lead to tyrosine phosphorylation 
of the kinases and thus affect the kinase activities. Third, oxidation stimulates proteolysis of 
regulatory proteins that may inhibit tyrosine kinase activity [130]. Hydrogen peroxide can 




protein kinase B (PKB) [131]. It was shown that UV-light induced ROS activates and 
dimerizes the Ret tyrosine kinase [132].  This effect was due to the presence of Cys residues 
in Ret tyrosine kinase. Block and colleagues found that NOX4 and ROS production was 
upregulated in angiotensin ΙΙ treated mesangial cells due to the oxidation of Src. They claim 
this step is important for angiotensin ΙΙ induced fibronectin accumulation [133]. 
 
Transcriptional factors 
A number of transcriptional factors can be regulated by redox signaling including AP-1, 
Hypoxia inducible factor-1(HIF-1α), p53, Nuclear factor kappa B (NF-κB) and NF-E2-related 
factor (Nrf2)[134]. These contains cysteine residues at their binding sites [17]. NF-κB is a 
redox sensitive transcriptional factor that regulates the expression of genes involved in 
immune and inflammatory responses [8, 19]. ROS has different effects on inhibition and 
activation of NF-κB and the activation depends on the level of ROS production, cell types and 
type of stimuli [135, 136]. In colon carcinoma cell lines mitochondrial ROS production during 
hypoxia plays a dual role by promoting the cell survival by NF-κB activation via c-Src or cell 
death by over production of ROS [137]. Hypoxia activates a number of transcriptional factors 
including HIF-1 and HIF-2. HIF-1 is composed of two subunits HIF1-α and β. The levels of 
HIF-1α is elevated under hypoxic conditions which allows translocation to the nucleus and 
subsequent dimerization with HIF1-β and binding to promoter elements [119]. Under 
normoxic conditions HIF will be stabilized by different stimuli by the increased production of 
ROS [17]. In addition, it has been shown that mitochondrial production of ROS, specially by 
complex ΙΙΙ, was necessary for stabilization of HIF-1α during hypoxia [138]. Hypoxia induces 
the early epithelial-mesenchymal transition (EMT) in cancer cells by the production of 
mitochondrial ROS and HIF-1α plays a role in increased invasiveness and migration [139].  In 
murine neuroblastoma cell line HIF-1α activation by mitochondrial ROS mediates the cyanide 
induced mitochondrial cell death through upregulation of BNIP3 (Bcl2/E1B 19 kDa 
interacting protein, member of the Bcl2 family) [140]. Under normal redox conditions Nrf2 
localizes with Kelch-like-ECH-associating protein 1(Keap1) in the cytoplasm. Keap1 contains 
Cys residues that are the targets of ROS. Oxidation of Cys triggers the dissociation of Keap1 
from Nrf2 allowing Nrf2 translocation into the nucleus and activation of stress-response genes 
[17, 22].    




2. Aims of the study 
 
The overall aim of this study was to analyse the expression of NOX family members in cancer 
cells and to address the link between intracellular ROS levels and the regulation of GGT 
expression and activity. More particularly we wanted to study:  
• the distribution pattern of NOX isoforms and their regulatory subunits in human 
cancer cells 
• the knockdown effect of p22phox on ROS production in Ishikawa cells 
• role of NOX produced ROS in the regulation of GGT activity 
• role of mitochondrial ROS production for GGT regulation 
• effects of mitochondrial uncouplers and protein kinase Cs on ROS production and 
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3. Summary of papers 
 
Paper I: 
This paper presents a RT-qPCR screen on the expression levels of NOX family members and 
their regulatory subunits in 19 human cancer cell lines and in xenograft tumours. The results 
of the study showed that: 
• all human cancer cell lines tested express a subset of NOX family members and 
regulatory subunits. However, no apparent correlation between expression pattern and 
cancer type could be identified, suggesting that each cancer cell lines needs to be 
tested individually. 
• NOX1, NOX2 and NOX5 were the NOX core proteins that were most frequently 
upregulated compared to the expression level in fibroblasts.  
• expression of NOX3 and NOX4 was found at very low levels or absent from most cell 
lines tested. 
• of the regulatory subunits tested, p67phox was most frequently upregulated compared 
to fibroblasts. 
• in xenograft tumors of two of these three cell lines, the NOX5 mRNA level was 
significantly increased compared to the expression level when the cell lines were 
grown in vitro. Only minor changes were found in expression level of p22phox. 
 
Paper II:  
In this paper the effect of endogenouse ROS levels on GGT expression and activity was 
investigated. Downregulation of NOX activity through stable knockdown of the NOX 
regulatory subunit p22phox was investigated in Ishikawa cells, and the effects of the NOX 
inhibitor apocynin and the NOX stimulator PMA was studied in HT-29 cells. The results of 
the study showed that: 
• knockdown of p22phox expression resulted in reduced production of ROS. 
• downregulation of p22phox levels reduced the expression of GGT. 
• activation of NOX with phorbol ester increases ROS production and induces GGT 
expression. 
• Apocynin treatment reduces both the ROS production and the GGT expression. 
 
 





In this study the role of mitochondrial derived ROS on GGT expression and activity was 
investigated. Two mitochondrial uncouplers and one electron transport modulator were used 
in HT-29 cells in order to alter the ROS levels. Then the combined effect of mitochondrial 
uncouplers together with PMA was investigated with regards to ROS production and GGT 
expression. The results obtained showed that:  
 
• Rottlerin and FCCP, two mitochondrial uncouplers, increased the ROS levels and 
resulted in elevated GGT mRNA transcription. 
• Rotenone which is a mitochondrial electron chain inhibitor, increased ROS levels but 
not significantly GGT mRNA expression and activity. 
• Incubations with uncouplers together with PMA resulted in a significantly high ROS 
levels, as well as increased GGT mRNA expression.  
• These combined incubations resulted also in increased GGT activity, but after a 














This thesis is based on my studies of the analysis of the ROS producing NOX complexes in 
cancer cells (paper I), the effect of NOX generated ROS on human GGT1 expression (paper 
II), and the role of mitochondrial ROS production together with NOX activation for the 
expression of GGT (paper III).  
 
In the first study (paper Ι) we have investigated the expression profile of the five members of 
the NOX gene family and their regulatory subunits in various cancer cell lines and tumour 
samples. The cell lines tested were human oral and skin squamous cell carcinoma (SCC) cell 
lines, as well as one adenocarcinoma and one melanoma cell line. Two normal human 
fibroblast cell lines were used as references. We also analyzed the expression in xenograft 
tumour of three of the cell lines.  
 
NOX core proteins and their regulatory subunits have been described to have cell type 
specific expression, localization and distribution [30]. It has been clearly shown that cancer 
tumours have elevated levels of ROS. Many signalling pathways are ROS sensitive, and 
alterations in the ROS levels may influence on these signalling pathways and potentially lead 
to cancer cell proliferation, prevention of apoptosis, survival and metastasis [13, 119, 141]. In 
cancer cells, high levels of ROS can result from increased metabolic activity, mitochondrial 
dysfunction, increased cellular receptor signaling and increased activity of oxidases such as 
the NOX family of oxidases [13]. Several studies have shown that oxidative stress may lead 
to tumour growth and metastasis [31, 142], and NOX1 has been reported to be highly 
expressed in several cancers including breast, ovarian, prostate and colon cancers [61, 143, 
144].   
 
Over 90% of the oral cancers are squamous cell carcinomas (SCCs) and they are the seventh 
most frequent cause of cancer death worldwide [145]. The overall survival rate for oral cancer 
patients is estimated to be 50% and this has not improved over the past two decades [146]. 
ROS production plays a major role in oral cancers, as well as in periodontitis, and it has also 
been shown that production of ROS can be induced through HIF-1α by chemotherapeutic 
drugs and gamma-rays in oral cancer [2, 40, 147-149]. It was found that blood and tumour 
tissues of oral SCC (OSCC) patients have increased levels of NO and decreased levels of 
catalase and SOD. This oxidant-antioxidant imbalance can leads to oxidative stress, one of the 





Currently there are no studies showing the distribution of NOX isoforms in head and neck 
cancer cell lines derived from patient tumours. Our results shows that the expression varies 
considerably between the cell lines, however all cell lines express two or more of the NOX 
core proteins and several of the regulatory subunits.  Thus, all cell lines in our set have the 
potential to produce ROS via the NOX system if they are adequately stimulated.  We also 
found that cell lines derived from the primary tumour and corresponding metastasis from 
same patient showed different expression patterns. This indicates that the expression pattern 
of NOX genes may change during the various stages of cancer progression.  We also analysed 
the mRNA expression of NOX5 and p22phox in xenograft tumours of three of the cell lines.  
The results showed that for two of these three cell lines the NOX5 mRNA level was 
significantly increased in the tumor tissues compared to the expression level when the cell 
lines were grown in vitro. Only minor changes were found in the expression level of p22phox.  
This indicates that the expression of NOX5 may be influenced by the growth conditions and 
in particular by the microenvironment. However, more studies are needed before concluding 
whether the expression levels found in the cell lines are changed from when the cells were 
part of the original tumor in the patient.   
 
In paper II we studied the effect of NOX produced ROS on the expression of GGT.  GGT is 
one of the key enzymes in the regeneration of the anti-oxidant glutathione (GSH), thus its 
expression levels and activity has major influence on the total oxidative stress burden of the 
cell. In order to study the relationship between NOX enzymes and GGT we used the Ishikawa 
and the HT-29 cell lines.  
 
Being able to measure intracellular ROS levels were essential for this study and we were able 
to establish a robust flow cytometric method for ROS quantification that could be used to 
monitor the changes in ROS levels as a consequence of the manipulations of the NOX 
enzymes. Phagocytic cells produce high levels of ROS compared to nonphagocytic cells, and 
many commercially available kits are available for detection of such high ROS levels. In our 
hands, these kits were not sensitive enough to be able to detect the low ROS levels in 
nonphagocytic cells. However they reliably measured ROS levels in phagocytic cell such as 
the THP-1 cells (data not shown). We chose to use the fluorescently labelled probe (CM-
H2DCFDA) that is redox sensitive (details on materials and methods paper ΙΙ) and succeeded 
to quantifying the ROS levels in nonphagocytic cells by Fluorescence Activated Cell Sorter 




   
Ishikawa is an endometrial adenocarcinoma cell line derived from an asian woman. These 
cells are well-differentiated and display estrogen and progesterone receptors in culture and in 
induced tumours [151]. We showed in paper I that this cell line expressed mRNA for all NOX 
core proteins and regulatory subunits including p22phox. Although it had less p67phox 
mRNA compared to the fibroblast cell lines used as references, we were able to show by flow 
cytometry that they produced detectable levels of intracellular ROS. The production of ROS 
through NOX 1-4 activity is regulated by different cytosolic subunits and p22phox plays a 
critical role for the activity of all these enzymes. p22phox binds with the other cytosolic 
subunits of the NOX proteins upon activation (only NOX 1-3) and also stabilises the NOX 
core protein [2, 3, 34, 43]. With the importance of p22phox for the activity of NOX1-4 
enzymes we had reasons to assume that knockdown of p22phox would effect the total level of 
ROS in the cell. We generated stable knockdown of p22phox Ishikawa cells using shRNA 
targeting p22phox and could show by flow cytometery that the ROS levels were lower than in 
clones stably tranfected with the control shRNA construct.  We obtained the same results in 
transiently transfected cell, excluding the possibility that the results were due to clonal 
variations.  
 
Several studies have shown that GGT expression can be upregulated after acute oxidative 
stress [26, 109, 152, 153]. However, it remains unclear whether changes in intracellular ROS 
levels following variation in NOX activity can alter GGT expression. To address this question 
we used Ishikawa p22phox knockdown cells to follow the GGT expression. The results 
showed that knockdown of p22phox reduces the mRNA expression of GGT-1 as well as GGT 
protein level and activity in Ishikawa cells (paper ΙΙ). This indicates that the NOX system 
have a potentially important role in the regulation of GGT. To support our finding we used 
the colon carcinoma cell line HT-29.  This cell line is known to express high levels of NOX1 
[154], which was also confirmed by our RT-qPCR results of HT-29 cells (data not shown). 
Treatment with apocynin, a NOX inhibitor, reduced the production of ROS and decreased the 
expression of GGT (paper ΙΙ). In addition, treatment with PMA, a stimulator of NOX activity 
[155], increased both the ROS levels and the expression of GGT (paper ΙΙ).  
 
Taken together, our results show that variations in the endogenous level of ROS generated by 
NOX are a significant determinant for basal GGT expression. Higher levels of oxidative stress 
are correlated with cancer malignancy and poor prognosis [103] which indicates that tumour 




20]. GGT may act as one of several adaptive responses to protect against severe oxidative 
stress and, as was suggested for melanoma therapy, GGT enzyme could thus be a target for 
cancer treatment. 
 
In paper ΙΙΙ we investigated the role of mitochondrial derived ROS on GGT and also whether 
the combined effect of mitochondrial and NOX production of ROS had additional influence 
on GGT expression.  
 
Mitochondrial electron transport chain is one of the major sources for ROS production. It is 
well known that complex Ι and ΙΙΙ are responsible for the ROS production in mitochondrial 
ETC [62, 65, 156]. Recent studies showing that there is a possible crosstalk between 
mitochondrial ROS and NOX for amplifying ROS signalling (per reviews [71, 157]). In paper 
ΙΙ we showed that GGT expression and activity can be regulated by cellular ROS production 
by NOX enzymes and in paper ΙΙΙ we used different modulators to address whether 
mitochondrial ROS can also have a role in GGT expression and activity.  
 
First we treated the HT29 cells with mitochondrial uncouplers rottlerin and FCCP. Rottlerin is 
originally reported as a protein kinase C inhibitor but it also works as mitochondria 
uncoupler. It reduces the ATP levels and depolarized the mitochondrial membrane potential. 
Recent data show that rottlerin upregulates the production of ROS in HT-29 cells and induces 
the heme oxygenase-1 through a PKCδ independent pathway [158-160]. We found that HT29 
cells produce high levels of ROS after treatment with rottlerin alone. To confirm this result 
we used FCCP, which is a classical and potent uncoupler of oxidative phosphorylation, and 
similar results were obtained. Both uncouplers also upregulated GGT mRNA transcription, 
but we failed to detect increases in GGT activity when measured after 4 days. The results 
indicates that mitochondrial ROS play a role in GGT regulation.  
 
Significantly higher ROS levels were found when cells were treated simultaneously with 
PMA and uncoupler. This increase was apparently higher than the summation of the levels of 
either PMA or uncoupler alone, indicating a crosstalk in ROS production between 
mitochondria and NOX activity [71]. In a study by Desouki et al it was shown that 
mitochondria can crosstalk with NOX1 mediated by ROS produced in the mitochondria [61]. 
As we know HT29 cells have a high expression of NOX1 we hypothesized that the cellular 
ROS production was from NOX1. The GGT mRNA expression was increased in these cells 




We were however, unable to verify that this amplification of ROS level was due to crosstalk, 
and also whether PKC activation takes part in the PMA effect. More studies will be needed 
for this, and also more selective inhibitors. The PKC inhibitors used, Ro 31-8220 and GF 
109203X (Gö6850) are not specific or selective for PKC isotypes. Ro 31-8220 was originally 
known as a PKC inhibitor but it also inhibits other kinases such as MAPK and ERK1/2, and 
activates JNK and glycogen synthase [161,162]. It was well known that H2O2 can activate 
several protein kinases including ERK1/2 [131]. In our experiments we found that Ro 31-
8220 showed decreased production of ROS and reduced GGT mRNA expression and activity. 
The other protein kinase inhibitor used, GF 109203X (Gö6850) may be selective for PKC α 
and β1 isoforms. This inhibitor showed significantly low levels of ROS production, GGT 
expression and activity when used with the HT29 cells. When we stimulated the cells with 
PMA together with GF 109203X high levels of ROS was detected along with increased GGT 
expression and activity levels. This may be due to the PMA, as we know that PMA is a potent 
activator of PKC. 
 
We were unable to detect increased GGT enzyme activity the first 4 days after rottlerin and 
FCCP incubations. This may be caused by endoplasmic reticulum (ER) stress. Lim et al have 
shown that in HT-29 cells rottlerin induce a number of ER markers [163]. In another study, 
Reuter et al demonstrated a similar time course of GGT activity increases following TNF-α 
incubation of leukemia cells that was caused by ER stress [105]. Similar results were obtained 
in our study following the FCCP treatment.  
 
Rotenone is a natural hydrophobic pesticide, which acts as a mitochondrial ETC1 inhibitor. It 
was shown that MCF-7 cells will produce high levels of ROS when treated with rotenone and 
can induce the apoptosis through JNK and p38 signalling [161]. We found that rotenone 













The main conclusions that can be drawn from this study are: 
 
• Of 22 human cancer cell lines tested, all expressed transcripts encoding two or more 
NOX core proteins and several of the regulatory subunits 
 
• the p67phox expression levels were higher in the metastatic tumour cells compare to 
primary tumour cells 
 
• ROS produced by NOX complexes are involved in regulating the expression of GGT 
 





6. Future studies 
Although the function of all NOX isoforms is to catalyze the reduction of molelular oxygen 
and by that produce ROS; they differ in their expression (paper Ι), subcellular localization, 
and mechanism for activation. Due to these differences it is hard to make conclusions about 
which NOX isoform is playing a role in cancer progression. Experiments such as knockdown 
studies will be an interesting approach in order to study these differences and to determine 
their role in cancer progression. In follow up studies of paper ΙΙ and ΙΙΙ it is important to 
determine which signalling pathways are responsible for the induction of GGT expression, 
both by the NOX systems and also mitochondrial ETC. In order to answers these questions it 
will be interesting to develop new cell lines with either up regulated or down regulated NOX 
isoforms and to test these cell lines in both in vitro and in vivo. These cell lines will be helpful 
to understand the role of NOX isoforms in disease progression. Now it is increasingly clear 
that inhibition of NOX enzymes is a promising pharmacologic concept for oxidative stress. 
To date there is no specific NOX inhibitors in clinical use. The new knowledge how ROS 
influences on cancer progression and studies on both oxidant systems like NOX and 
mitochondria and also the role of antioxidants on these systems will be useful to design 
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